Xin-Ming Shen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5787684/publications.pdf Version: 2024-02-01



XIN-MINC SHEN

#	Article	IF	CITATIONS
1	Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurology, The, 2015, 14, 420-434.	4.9	413
2	Rapsyn Mutations in Humans Cause Endplate Acetylcholine-Receptor Deficiency and Myasthenic Syndrome. American Journal of Human Genetics, 2002, 70, 875-885.	2.6	221
3	Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nature Reviews Neuroscience, 2003, 4, 339-352.	4.9	212
4	Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7377-7382.	3.3	176
5	Congenital Myasthenic Syndromes due to Heteroallelic Nonsense/Missense Mutations in the Acetylcholine Receptor Subunit Gene: Identification and Functional Characterization of Six New Mutations. Human Molecular Genetics, 1997, 6, 753-766.	1.4	164
6	The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Annals of Neurology, 2000, 47, 162-170.	2.8	123
7	Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nature Neuroscience, 1999, 2, 226-233.	7.1	119
8	Dokâ€7 myasthenia: Phenotypic and molecular genetic studies in 16 patients. Annals of Neurology, 2008, 64, 71-87.	2.8	117
9	Mode Switching Kinetics Produced by a Naturally Occurring Mutation in the Cytoplasmic Loop of the Human Acetylcholine Receptor ε Subunit. Neuron, 1998, 20, 575-588.	3.8	109
10	Myopathy, Myasthenic Syndrome, and Epidermolysis Bullosa Simplex Due to Plectin Deficiency. Journal of Neuropathology and Experimental Neurology, 1999, 58, 832-846.	0.9	104
11	Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. Neurology, 2014, 83, 2247-2255.	1.5	102
12	LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Human Molecular Genetics, 2014, 23, 1856-1868.	1.4	96
13	What Have We Learned from the Congenital Myasthenic Syndromes. Journal of Molecular Neuroscience, 2010, 40, 143-153.	1.1	82
14	Mutation causing severe myasthenia reveals functional asymmetry of AChR signature cystine loops in agonist binding and gating. Journal of Clinical Investigation, 2003, 111, 497-505.	3.9	68
15	hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome. Human Molecular Genetics, 2008, 17, 4022-4035.	1.4	54
16	GFPT1-myasthenia. Neurology, 2013, 81, 370-378.	1.5	54
17	PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology, 2014, 82, 1254-1260.	1.5	52
18	Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurology: Genetics, 2016, 2, e105.	0.9	50

XIN-MING SHEN

#	Article	IF	CITATIONS
19	Congenital myasthenia–related AChR δ subunit mutation interferes with intersubunit communication essential for channel gating. Journal of Clinical Investigation, 2008, 118, 1867-1876.	3.9	50
20	Congenital Myasthenic Syndromes: Multiple Molecular Targets at the Neuromuscular Junction. Annals of the New York Academy of Sciences, 2003, 998, 138-160.	1.8	49
21	DPAGT1 myasthenia and myopathy. Neurology, 2014, 82, 1822-1830.	1.5	48
22	Urine-Derived Compound Evokes Membrane Responses in Mouse Vomeronasal Receptor Neurons. Journal of Neurophysiology, 1997, 77, 2856-2862.	0.9	47
23	Slow-channel mutation in acetylcholine receptor αM4 domain and its efficient knockdown. Annals of Neurology, 2006, 60, 128-136.	2.8	44
24	Functional consequences and structural interpretation of mutations of human choline acetyltransferase. Human Mutation, 2011, 32, 1259-1267.	1.1	43
25	Beneficial effect of albuterol in congenital myasthenic syndrome with epsilonâ€subunit mutations. Muscle and Nerve, 2011, 44, 289-291.	1.0	42
26	Impaired Synaptic Development, Maintenance, and Neuromuscular Transmission in LRP4-Related Myasthenia. JAMA Neurology, 2015, 72, 889.	4.5	41
27	Endplate structure and parameters of neuromuscular transmission in sporadic centronuclear myopathy associated with myasthenia. Neuromuscular Disorders, 2011, 21, 387-395.	0.3	39
28	Novel synaptobrevinâ€1 mutation causes fatal congenital myasthenic syndrome. Annals of Clinical and Translational Neurology, 2017, 4, 130-138.	1.7	38
29	Congenital myasthenic syndromes in adult neurology clinic. Neurology, 2018, 91, e1770-e1777.	1.5	36
30	A frameshifting mutation in CHRNE unmasks skipping of the preceding exon. Human Molecular Genetics, 2003, 12, 3055-3066.	1.4	29
31	Subunit-specific contribution to agonist binding and channel gating revealed by inherited mutation in muscle acetylcholine receptor M3-M4 linker. Brain, 2004, 128, 345-355.	3.7	29
32	<i>Further Observations in Congenital Myasthenic Syndromes</i> . Annals of the New York Academy of Sciences, 2008, 1132, 104-113.	1.8	28
33	Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up. Neuromuscular Disorders, 2018, 28, 315-322.	0.3	28
34	Highly fatal fast-channel syndrome caused by AChR É [,] subunit mutation at the agonist binding site. Neurology, 2012, 79, 449-454.	1.5	27
35	New horizons for congenital myasthenic syndromes. Annals of the New York Academy of Sciences, 2012, 1275, 54-62.	1.8	24
36	Electrophysiological and Biochemical Responses of Mouse Vorneronasal Receptor Cells to Urine-derived Compounds: Possible Mechanism of Action. Chemical Senses, 1998, 23, 483-489.	1.1	23

XIN-MING SHEN

#	Article	IF	CITATIONS
37	Myasthenic syndrome AChRα C-loop mutant disrupts initiation of channel gating. Journal of Clinical Investigation, 2012, 122, 2613-2621.	3.9	23
38	The Spectrum of Congenital Myasthenic Syndromes. Molecular Neurobiology, 2002, 26, 347-367.	1.9	21
39	Congenital myasthenic syndromes: A diverse array of molecular targets. Journal of Neurocytology, 2003, 32, 1017-1037.	1.6	20
40	Mutations Causing Slow-Channel Myasthenia Reveal That a Valine Ring in the Channel Pore of Muscle AChR is Optimized for Stabilizing Channel Gating. Human Mutation, 2016, 37, 1051-1059.	1.1	19
41	Limb girdle muscular dystrophy D3 HNRNPDL related in a Chinese family with distal muscle weakness caused by a mutation in the prion-like domain. Journal of Neurology, 2019, 266, 498-506.	1.8	19
42	Congenital myasthenic syndrome in Japan: Ethnically unique mutations in muscle nicotinic acetylcholine receptor subunits. Neuromuscular Disorders, 2015, 25, 60-69.	0.3	18
43	Atypical familial amyotrophic lateral sclerosis with initial symptoms of pain or tremor in a Chinese family harboring VAPB-P56S mutation. Journal of Neurology, 2016, 263, 263-268.	1.8	18
44	Mechanistic Diversity Underlying Fast Channel Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 2003, 998, 128-137.	1.8	13
45	A homozygous mutation in GMPPB leads to centronuclear myopathy with combined pre- and postsynaptic defects of neuromuscular transmission. Neuromuscular Disorders, 2019, 29, 614-617.	0.3	11
46	Investigation of Congenital Myasthenia Reveals Functional Asymmetry of Invariant Acetylcholine Receptor (AChR) Cys-loop Aspartates. Journal of Biological Chemistry, 2016, 291, 3291-3301.	1.6	10
47	Monoclonal gammopathy with both nemaline myopathy and amyloid myopathy. Neuromuscular Disorders, 2017, 27, 942-946.	0.3	10
48	Mutations causing congenital myasthenia reveal principal coupling pathway in the acetylcholine receptor Îμ-subunit. JCI Insight, 2018, 3, .	2.3	8
49	The unfolding landscape of the congenital myasthenic syndromes. Annals of the New York Academy of Sciences, 2018, 1413, 25-34.	1.8	7
50	Slow hannel myasthenia due to novel mutation in M2 domain of AChR delta subunit. Annals of Clinical and Translational Neurology, 2019, 6, 2066-2078.	1.7	7
51	Congenital Myasthenic Syndrome Caused by Novel Loss-of-Function Mutations in the Human AChR e Subunit Genea. Annals of the New York Academy of Sciences, 1998, 841, 184-188.	1.8	6
52	Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia. Neurology, 2020, 95, e2781-e2793.	1.5	5
53	A novel fast-channel myasthenia caused by mutation in Î ² subunit of AChR reveals subunit-specific contribution of the intracellular M1-M2 linker to channel gating. Experimental Neurology, 2020, 331, 113375.	2.0	5
54	Presence of antibodies against low-density lipoprotein receptor-related protein 4 and impairment of neuromuscular junction in a Chinese cohort of amyotrophic lateral sclerosis. Chinese Medical Journal, 2019, 132, 1487-1489.	0.9	4

XIN-MING SHEN

#	Article	IF	CITATIONS
55	Missense Mutations of Codon 116 in the SOD1 Gene Cause Rapid Progressive Familial ALS and Predict Short Viability With PMA Phenotype. Frontiers in Genetics, 2021, 12, 776831.	1.1	2
56	LRP4 myasthenia: Investigation of a second kinship reveals impaired development and maintenance of the neuromuscular junction. Neuromuscular Disorders, 2015, 25, S186-S187.	0.3	1
57	A unique case of dysferlinopathy with a large-segment duplication mutation who experienced rapid deterioration after small-dosage corticosteroid treatment. Journal of the Neurological Sciences, 2017, 376, 35-37.	0.3	1
58	CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. Journal of Neuroimmunology, 2021, 355, 577571.	1.1	1
59	Charcot–Marie–Tooth Disease With Episodic Rhabdomyolysis Due to Two Novel Mutations in the β Subunit of Mitochondrial Trifunctional Protein and Effective Response to Modified Diet Therapy. Frontiers in Neurology, 2021, 12, 694966.	1.1	1
60	G.P.11.11 Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients. Neuromuscular Disorders, 2009, 19, 626-627.	0.3	0